Literature DB >> 11897046

A novel 196Leu to Pro substitution in the beta3 subunit of the alphaIIbbeta3 integrin in a patient with a variant form of Glanzmann thrombasthenia.

Alan T Nurden1, Jian Ruan, Jean-Max Pasquet, Bruno Gauthier, Robert Combrié, Thomas Kunicki, Paquita Nurden.   

Abstract

Glanzmann thrombasthenia (GT) is an inherited disorder where an absence of platelet aggregation is associated with quantitative or qualitative abnormalities of the alphaIIbbeta3 integrin. In rare patients, amino acid substitutions have provided information on the functional significance of specific domains within alphaIIb or beta3. We now report an elderly male GT patient (R.M.) from the south west of France whose platelets possess a small residual expression of alphaIIbbeta3. Furthermore, the integrin failed to undergo the necessary conformational changes following platelet activation to permit the binding of fibrinogen or activation-dependent monoclonal antibodies despite the presence of an RGD-binding site. Screening of the alphaIIb and beta3 genes by PCR-SSCP revealed a heterozygous mutation at position 685 in exon 5 of the beta3 gene leading to a 196Leu to Pro substitution. 196Leu is a highly conserved amino acid of beta3. The other beta3 allele appeared to be silent. This mutation, inherited from his mother and present in other family members with intermediate levels of alphaIIbbeta3, was close to the MIDAS-like domain of beta3, a fact that appears to explain its effect on alphaIIbbeta3 activation and fibrinogen binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897046     DOI: 10.1080/09537100220122466

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  8 in total

1.  Identification of integrin beta subunit mutations that alter affinity for extracellular matrix ligand.

Authors:  Timmy Kendall; Leona Mukai; Alison L Jannuzi; Thomas A Bunch
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 2.  Glanzmann thrombasthenia: state of the art and future directions.

Authors:  Alan T Nurden; Xavier Pillois; David A Wilcox
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

Review 3.  Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options.

Authors:  Tia Solh; Ashley Botsford; Melhem Solh
Journal:  J Blood Med       Date:  2015-07-08

4.  Management of Dentoalveolar Trauma in a 3-year-old Child with Glanzmann's Thrombasthenia, a Rare Bleeding Disorder: Case Report and Review.

Authors:  Rakesh N Bahadure; Vijaya Dhote; Kulsum Iqbal Sayed; Sandeep Bailwad; Poornima Kodate
Journal:  Contemp Clin Dent       Date:  2019 Jan-Mar

Review 5.  A Comprehensive Review of Congenital Platelet Disorders, Thrombocytopenias and Thrombocytopathies.

Authors:  Gisha Mohan; Srikrishna V Malayala; Parth Mehta; Mamtha Balla
Journal:  Cureus       Date:  2020-10-31

6.  Molecular dynamics analysis of a novel β3 Pro189Ser mutation in a patient with glanzmann thrombasthenia differentially affecting αIIbβ3 and αvβ3 expression.

Authors:  Michel Laguerre; Essa Sabi; Martina Daly; Jacqueline Stockley; Paquita Nurden; Xavier Pillois; Alan T Nurden
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

7.  Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study.

Authors:  Isabel Sánchez-Guiu; Ana I Antón; José Padilla; Francisco Velasco; José F Lucia; Miguel Lozano; Ana Rosa Cid; Teresa Sevivas; María F Lopez-Fernandez; Vicente Vicente; Consuelo González-Manchón; José Rivera; María L Lozano
Journal:  Orphanet J Rare Dis       Date:  2014-12-24       Impact factor: 4.123

8.  Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of thirty-two Turkish patients with Glanzmann thrombasthenia: a multicenter experience

Authors:  Berkay Saraymen; Sabahattin Muhtaroğlu; Mustafa Yavuz Köker; Nazan Sarper; Emine Zengin; Canan Albayrak; Davut Albayrak; Bülent Zülfikar; Başak Koç Şenol; Esma Bentli; Semih Yılmaz; Aysun Çetin; Bülent Eser; Mustafa Çetin
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.